LILLE, France–At the 15th Annual Society for Biomolecular Sciences (SBS) Conference today, PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, and Cerep SA, a leading provider of drug candidate screening and profiling technologies, announced the expansion of their kinase assay offering. Close to 200 new kinase assays validated with PerkinElmer’s LANCE® UltraTM technology will be offered for use through Cerep’s drug candidates selection and qualification services.

The collaboration between the two companies first announced in April 2008 delivers custom drug discovery services, through a combination of PerkinElmer’s leading assay technologies, and Cerep’s unique target screening and drug discovery offerings. Key therapeutic research pathways supported by the new 189 kinase assays include cancer, cardiac disease, central nervous system disorders, inflammation, diabetes, and metabolic disorders, amongst others.

“The extensive range of high quality kinase assays now available for screening and profiling through this collaboration is a compelling complement to the profiling services offered by Cerep. It provides our customers with the expansive range of products and expertise necessary for broad compound screening campaigns to aid their research,” said Richard M. Eglen, PhD, president, Bio-discovery, PerkinElmer. “Our clients can now benefit from testing their compounds against a broad range of kinase targets via a single platform, validated for performance with PerkinElmer’s innovative LANCE Ultra portfolio and diversified UlightTM substrates, for consistently high quality results.”

“Cerep is delighted with the extension of our combined capabilities with PerkinElmer represented by this expansion of kinase offerings to our clients,” said Thierry Jean, chairman and chief executive officer, Cerep SA. “This initial success of our collaboration is validation that our combined model of assays and screening enables clients to avoid time consuming and costly in-house assay development by taking their compounds directly into high throughput screening and profiling against the desired drug targets.”

The collaboration with Cerep provides PerkinElmer customers with an option to work with a single vendor throughout the entire drug discovery process. Cerep customers in turn have access to several key assay development and detection platforms from PerkinElmer’s Bio-discovery business, including AlphaScreen®, AlphaLISA®, LANCE®, LANCE® Ultra™ and radioligand binding assays for G protein-coupled receptor (GPCR) and kinase assay development.

About Cerep SA

Focussing on in vitro pharmacology and ADME-Tox, Cerep (Nyse Euronext – CER) provides solutions allowing cost-effective drug discovery by identifying at early stages the most promising drug candidates and eliminating compounds likely to fail in development. Cerep’s technologies benefit to more than 460 pharmaceutical and biotechnological companies worldwide including most of the top pharmaceutical firms.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $2 billion in 2008, has around 8,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.